Lilly Launches AI-Powered Platform to Accelerate Breakthrough Medicines

Strategic Insights -

Eli Lilly and Company announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data. The platform is part of Lilly Catalyze360's offerings for early-stage biotech companies, aiming to accelerate the creation of new medicines for patients.

Key Takeaways:

  • Lilly TuneLab is an AI/ML platform that provides biotech companies access to Lilly-trained artificial intelligence models, utilizing proprietary data obtained at a cost of over $1 billion.
  • The platform is designed to be an equalizer, allowing smaller companies to access AI capabilities used by Lilly scientists, and is hosted by a third-party using federated learning, a privacy-preserving approach.
  • Lilly TuneLab was developed through partnerships with leading global technology providers and AI/ML experts, and is the newest addition to Lilly Catalyze360's offerings for biotech partners.
  • The platform includes proprietary data obtained at a cost of over $1 billion, representing one of the industry's most valuable datasets used to train an AI system available to biotechnology companies.
  • Lilly estimates that the first release of AI models includes critical insights into drug discovery, allowing biotech companies to unlock novel scientific insights and make smart development decisions earlier.
  • Lilly TuneLab is part of a broader effort by Lilly to accelerate breakthrough medicines, through its programs Lilly Catalyze360, Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D.
  • Nisha Nanda, Ph.D., group vice president and head, Lilly Catalyze360, stated, "With Lilly TuneLab we're not just sharing resources, we are also compressing decades of learning into instantly accessible intelligence."

Statistics:

  • Lilly estimates that the AI models on Lilly TuneLab were trained on proprietary data obtained at a cost of over $1 billion.
  • The AI models include data representing hundreds of thousands of unique molecules.
  • Lilly TuneLab is hosted by a third-party and employs federated learning, a privacy-preserving approach that enables biotechs to tap into Lilly's AI models without directly exposing their proprietary data or Lilly's.

Sources:

  • Eli Lilly and Company (PRNewswire, Sept. 9, 2025)
  • Lilly (lilly.com, About Lilly)